Genoskin launches the ISR platform®: the first human skin ex vivo platform to study injection site reactions (ISR) ahead of clinical trials
Genoskin is evolving and aims to support the biotech and pharmaceutical industries in accelerating their drug development.
Today, July 6th 2021, Genoskin announces the launch of the ISR platform®, a new pre-clinical toolbox designed to study injection site reactions (ISR) in humans ahead of clinical trials. The company has filed intellectual property to protect its transformative platform worldwide. With the ISR platform®, Genoskin can support the development of safer new biologics by characterizing mast cell-dependent (pseudo-allergy) or -independent inflammatory skin adverse events. The platform is available immediately for clients worldwide.
Subcutaneous injected biologics have emerged as a major focus within the pharmaceutical industry, thanks to lower-cost effectiveness, shorter administration time leading to better therapy compliance, possibilities of new patent protection when changing route of administration for the sponsor, etc. However, this method is not free from side effects: patients commonly experience moderate to severe reactions at the site of injection, including swelling, erythema, pruritus or pain. 100% of biologics can lead to injection site reaction, which is the most reported adverse effect. The current lack of research tools to study injections in humans makes development of such therapeutic molecules very challenging, especially when animal testing is the only option for companies.
With its patented technologies and the patent-pending ISR Platform®, Genoskin provides researchers globally with a new turnkey solution, enabling the testing of subcutaneous biologics in ready-to-use, standardized, fully immunocompetent and injectable ex vivo human skin models. Based on living and healthy human skin, the company’s proprietary technology maintains the tissue in a functional survival state for at least seven days. The ISR platform®, also incorporates complementary technologies leveraging Genoskin’s ability to produce and culture human primary mast cells. Testing of multiple conditions in parallel and in the same donor is now possible. This provides drug developers with earlier access to true – not predicted or emulated – first-in-human data, ahead of clinical trials.
Validated by recognized industry partner Catalyst Biosciences
Catalyst Biosciences (NASDAQ: CBIO), a biopharmaceutical company focused on hematology disorders, was an early adopter of Genoskin’s ISR platform. A phase 1/2b study clearly demonstrated that DalcA, used in patients with Hemophilia B, was well tolerated and efficacious with the absence of bleeding events through washout. However, some subjects reported mild to moderate injection site reactions (ISRs) of pain and/or redness following initial subcutaneous injections. In order to find a better formulation for the drug, the company leveraged the Genoskin HypoSkin® ex vivo model to perform histological, cellular and proteomic assays. Study demonstrated that DalcA activated the Mass-related G protein-coupled receptor X2 (MRGPRX2), a specific receptor found on skin resident mast cells. Testing different variations, Catalyst Biosciences was able to identify a new formulation buffer for DalcA with a favorable proteomic signature in ex vivo human skin, suggesting a lower risk of clinical ISRs appearance. An abstract was released on July 2nd and will be presented at the ISTH 2021 on July 19th.
“We have successfully identified a new formulation for DalcA that seems to have a lower risk of leading to ISRs, using Genoskin’s unique platform” Catalyst Bioscience
Comments are closed.